Sign Up Today and Learn More About Curebase Stock
Invest in or calculate the value of your shares in Curebase or other pre-IPO companies through EquityZen's platform.
Curebase Stock (CURB)
Curebase is a provider of decentralized clinical research software solutions and services to patients and medical providers.
About Curebase Stock
Founded
2017
Headquarters
San Francisco, CA, US
Industries
Software, Health Care
Curebase builds a digital clinical trial assistant that would alter how medical providers discover, activate, and administer clinical trials for their patients. It aims to run clinical trials faster and cheaper than anyone else via software that reduces recruitment times, automates manual steps, and lets drug companies distribute their trials to clinics. The company was established in 2017 and is based in San Francisco, California.
Curebase Press Mentions
Stay in the know about the latest news on Curebase
Five decentralized clinical trial organizations raising big VC cash
outsourcing-pharma • May 05, 2024
Decentralized trials startup Curebase scraps clinical operations business unit, narrows in on software platform
endpts • Aug 05, 2023
Prodigi.ai, the AI-powered Digital Diagnostic Platform Acquires Coimbatore-based Data Analytics Platform CubeBase
indianweb2 • Jan 24, 2023
Curebase Celebrates Year of Growth, Organizational Maturity
prnewswire • Jan 04, 2023
Curebase Partners with Redenlab to Expand Data Capture Capabilities in Pharma Trials
prnewswire • Dec 02, 2022
Investors in Curebase
Discover investors in Curebase stock and explore their portfolio companies
Curebase Management
Leadership team at Curebase
Founder & CEO
Tom Lemberg
CTO
Matthew Rials
Join now and verify your accreditation status to gain access to:
- Curebase current valuation
- Curebase stock price
- Available deals in Curebase and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Curebase Stock
How to invest in Curebase stock?
Accredited investors can buy pre-IPO stock in companies like Curebase through EquityZen funds. These investments are made available by existing Curebase shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Curebase stock?
Shareholders can sell their Curebase stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
